Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls

MS Hofman, RJ Hicks, T Maurer, M Eiber - Radiographics, 2018 - pubs.rsna.org
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is
overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity …

Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology

TA Hope, JZ Goodman, IE Allen, J Calais… - Journal of Nuclear …, 2019 - Soc Nuclear Med
68Ga-PSMA-11 PET is used to stage patients with prostate cancer. We performed an
updated metaanalysis that separates imaging at the time of diagnosis and at the time of …

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective …

MS Hofman, N Lawrentschuk, RJ Francis, C Tang… - The Lancet, 2020 - thelancet.com
Background Conventional imaging using CT and bone scan has insufficient sensitivity when
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …

Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

S Sheikhbahaei, A Afshar-Oromieh, M Eiber… - European journal of …, 2017 - Springer
Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a …

H Grünig, A Maurer, Y Thali, Z Kovacs, K Strobel… - European Journal of …, 2021 - Springer
Purpose Improved logistics and availability led to a rapid increase in the use of [18 F]-PSMA-
1007 for prostate cancer PET imaging. Initial data suggests increased uptake in benign …

Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a …

J Kuten, I Fahoum, Z Savin, O Shamni… - Journal of Nuclear …, 2020 - Soc Nuclear Med
18F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)–based
radiopharmaceutical for imaging prostate cancer (PCa). The aim of this study was to …

Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly …

A Stabile, A Pellegrino, E Mazzone… - European Urology …, 2022 - Elsevier
Context The role of positron emission tomography/computed tomography (PET/CT) with
prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate …

Prostate-specific membrane antigen ligands for imaging and therapy

M Eiber, WP Fendler, SP Rowe, J Calais… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate
cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over …

PSMA ligands for PET imaging of prostate cancer

SM Schwarzenboeck, I Rauscher… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-
labeled PET agents has become increasingly important in recent years. Imaging of …

68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review

J Corfield, M Perera, D Bolton, N Lawrentschuk - World journal of urology, 2018 - Springer
Purpose To systematically review currently available data on 68 Ga-prostate specific
membrane antigen (PSMA) positron emission tomography (PET) used for the primary …